Get Your Personalized Supplement StackSupplement Stack Quiz

Capros

Also known as: Emblica officinalis, Indian Gooseberry, Amla, Capros, Phyllanthus emblica

Overview

Capros is a proprietary, standardized extract derived from the fruit of *Phyllanthus emblica*, commonly known as Indian Gooseberry or Amla. It is primarily utilized as a dietary supplement to support cardiovascular health by positively influencing lipid profiles and inflammatory markers. The extract is rich in beneficial polyphenols, particularly galloelagic acid derivatives, which are believed to be responsible for its antioxidant and anti-inflammatory properties. Research on Capros and other *Phyllanthus emblica* extracts indicates a moderate level of maturity, with several randomized controlled trials (RCTs) and meta-analyses available. While systematic reviews specifically on Capros are limited, the overall evidence quality is moderate, consistently demonstrating statistically significant effects on cardiovascular risk factors in overweight or dyslipidemic adults. Capros is designed to provide a consistent concentration of these active compounds to ensure efficacy.

Benefits

Capros offers several evidence-based benefits, primarily focused on cardiovascular health. It has been shown to significantly reduce low-density lipoprotein cholesterol (LDL-C) and the total cholesterol to high-density lipoprotein cholesterol (TC/HDL) ratio, with reductions of approximately 10-15% in LDL-C observed over 12 weeks. It also decreases high-sensitivity C-reactive protein (hs-CRP), a key inflammatory marker associated with cardiovascular disease (CVD) risk. Meta-analyses of *Emblica officinalis* fruit consumption further support reductions in triglycerides (TG), very low-density lipoprotein cholesterol (VLDL-C), and improvements in HDL-C. Beyond lipid modulation, Capros may downregulate platelet aggregation, potentially reducing the risk of thrombosis, and improve lipid ratios like the atherogenic index of plasma (AIP) and apolipoprotein B/apolipoprotein A1 ratio, which are strong predictors of CVD risk. These benefits are most pronounced in overweight or Class-1 obese adults and individuals with dyslipidemia. Effects typically become noticeable after 8-12 weeks of consistent daily supplementation.

How it works

Capros exerts its beneficial effects primarily through its rich polyphenol content, particularly galloelagic acid derivatives. These compounds act as potent antioxidants, scavenging free radicals and mitigating oxidative stress, a key contributor to cardiovascular disease. Its anti-inflammatory properties are mediated by the downregulation of pro-inflammatory cytokines and hs-CRP, thereby reducing systemic inflammation. The lipid-lowering effects are thought to involve the modulation of enzymes involved in lipid metabolism and an improvement in the body's ability to clear lipids from the bloodstream. Furthermore, Capros appears to inhibit platelet aggregation by influencing ADP and collagen receptor signaling pathways, which can contribute to a reduced risk of blood clot formation. The standardization of Capros ensures a consistent concentration of these active polyphenols, optimizing its oral bioavailability and efficacy.

Side effects

Capros is generally well tolerated, with clinical studies demonstrating good safety profiles at doses up to 1000 mg/day for 12 weeks. The incidence of side effects is rare and typically mild, with occasional reports of gastrointestinal discomfort. No significant drug interactions or contraindications have been reported in high-quality clinical trials specifically on Capros. However, due to its potential effects on platelet aggregation, caution is advised when used concurrently with anticoagulant or antiplatelet medications, although no direct interactions have been definitively established. Safety data for special populations, such as pregnant or breastfeeding women and children, are currently insufficient, and therefore, its use in these groups is not recommended without medical supervision. As with any supplement, individuals with pre-existing medical conditions or those taking prescription medications should consult a healthcare professional before starting Capros.

Dosage

The minimum effective dose of Capros, as established in clinical trials, is 500 mg taken twice daily, totaling 1000 mg per day. The optimal dose range typically falls between 500 mg and 1000 mg twice daily, depending on the specific formulation and individual tolerance. While studies have shown good safety at 1000 mg twice daily for 12 weeks, a clear maximum safe dose for long-term use has not been definitively established. For optimal absorption and to minimize potential gastrointestinal discomfort, Capros is generally recommended to be taken orally with meals. It is crucial to use a standardized extract, such as Capros, which is typically standardized to contain 30-35% galloelagic acid tannins, to ensure consistent potency and efficacy across different batches.

FAQs

Is Capros safe for long-term use?

Clinical trials have demonstrated Capros's safety for up to 12 weeks of use. However, data on its safety for longer-term use are currently limited, so extended use should be discussed with a healthcare professional.

How soon can benefits be expected?

Improvements in lipid profiles and inflammatory markers, such as LDL-C and hs-CRP, are typically observed after 8 to 12 weeks of consistent daily supplementation with Capros.

Can Capros replace statins?

While Capros shows lipid-lowering effects, it is not a substitute for prescription statin medications, especially for high-risk patients. It may be considered as an adjunctive therapy under medical guidance.

Are there any known drug interactions?

No significant drug interactions have been reported in controlled trials. However, due to its potential effects on platelet aggregation, caution is advised if taking anticoagulant or antiplatelet medications.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC4390209/ – This study investigated the effects of 1000 mg/day Capros in overweight adults over 12 weeks. It reported significant reductions in LDL-C, TC/HDL ratio, hs-CRP, and platelet aggregation, suggesting cardiovascular benefits. The study was limited by the absence of a placebo group and a moderate sample size.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10251691/ – This systematic review and meta-analysis evaluated various *Emblica officinalis* fruit extracts, including Capros, for their effects on cardiovascular risk factors. It found significant improvements in LDL-C, HDL-C, TG, and hs-CRP compared to placebo, supporting the overall efficacy of Amla extracts in lipid and inflammation modulation.
https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-019-2430-y – This double-blind, placebo-controlled RCT examined an aqueous amla extract with comparable polyphenol content to Capros. It demonstrated significant reductions in TC, TG, LDL-C, VLDL-C, and improved HDL-C and apolipoprotein ratios over 12 weeks, reinforcing the lipid-modulating effects of *Phyllanthus emblica* extracts.